Biotechnology company Pandorum Technologies has raised $18 million in a Series B funding round to advance and market tissue regenerative therapies. Pandorum specialises in programmable regenerative ...

Pandorum Technologies has raised $18 million in a Series B funding round to advance clinical development and expand market access for its regenerative therapies. The India and US-based biotechnology ...

Biotechnology firm Pandorum Technologies has raised $18 million (Rs 163 crore) in a Series B round to advance the clinical development of its therapies that target diseases on the surface of the eye.

Pandorum Technologies, a biotechnology company focused on programmable regenerative medicine, has raised $18 million in a Series B funding round to advance clinical development and expand global ...

The funding round led by Protons Corporate, with participation from Galentic Pharma, Noblevast Advisory and Avinya Fund, Burman Family, among others The fresh capital will be deployed to advance the ...

Tom Bowen is a senior editor who loves adventure games and RPGs. He's been playing video games for several decades now and writing about them professionally since 2020. Although he dabbles in news and ...

March 5, 2026: We added one new Clash Royale QR code for the Skeleton Shield emote. What are the new Clash Royale codes? If you're looking for new emotes and other freebies in Clash Royale, redeem ...

If you're looking for Blox Fruits codes, IGN has what you need! In this article, you'll find all the latest and working Blox Fruits codes in March 2026 that you can redeem for free rewards and bonuses ...

BENGALURU, India & SAN CARLOS, Calif.--(BUSINESS WIRE)--#BharatBiotech--Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with operations in India and the ...

Funding accelerates clinical development and market access across the U.S., Asia, and the Middle East Pandorum Technologies, a biotechnology company pioneering programmable regenerative medicine, with ...

QuantX will deploy Series B proceeds toward IND-enabling advancement of oral STAT6 and IL-17 inhibitors in immunology/inflammation and continued discovery expansion on its computational platform.